Chaperone Therapeutics

company

About

Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding

  • 11 - 50

Details

Last Funding Type
Grant
Industries
Pharmaceutical,Therapeutics
Founded date
Jan 1, 2009
Number Of Employee
11 - 50
Operating Status
Active

Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding: the underlying causes of neurodegenerative and other rare diseases.Their therapeutic approaches elevate the natural protein folding and stress protection mechanisms to prevent protein misfolding and the ensuing cell dysfunction and death. Chaperone’s unique drug discovery platforms, broad knowledge in small molecule optimization and expertise in animal models of protein misfolding disease and clinical evaluation propel their therapeutic discovery programs forward.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
Chaperone Therapeutics has raised a total of — in funding over 2 rounds. Their latest funding was raised on Sep 6, 2016 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 6, 2016 Grant 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Chaperone Therapeutics is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Grant